Amicus Therapeutics Secures FDA Approval for Pombiliti and Opfolda Combination Therapy
Amicus Therapeutics (NASDAQ: FOLD), headquartered in the United States, has announced that it has received...
Drug
Transcenta Secures FDA Approval for Phase III Trial of Osemitamab
China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received approval from the...
Takeda Receives FDA Approval for Subcutaneous Entyvio as UC Maintenance Therapy
The US Food and Drug Administration (FDA) has granted Japan’s Takeda Pharmaceuticals (TYO: 4502) regulatory...
Eli Lilly’s Insulin Biosimilar YouBiAn Approved for Diabetes Treatment in China
US pharmaceutical major Eli Lilly (NYSE: LLY) has announced that it has received market approval...
Everest Medicines’ Xerava Receives Marketing Approval from TFDA for cIAI Treatment
Everest Medicines (HKG: 1952) has announced that it has received marketing approval for its antibiotic...
Konruns Pharmaceutical’s KC1036 Pediatric Indication Accepted for NMPA Review
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced that the National Medical Products Administration...
Elpiscience Biopharmaceuticals Initiates Phase I Trial for Anti-LILRB2 Antibody ES009
Elpiscience Biopharmaceuticals, a China-based biopharmaceutical company, has announced that the first patient has been dosed...
Tasly Pharmaceuticals Gets NMPA Approval for B1344 Clinical Study in NASH
Tasly Pharmaceuticals (SHA: 600535), a China-based pharmaceutical company, has announced that it has received approval...
ImmuneOnco Initiates Phase I Trial for CD24-Targeted Monoclonal Antibody IMM47
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the first patient dosing in a...
Mabwell Bioscience Initiates Phase Ib/II Study for Nectin-4 Targeting ADC 9MW2821
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced the first...
LEO Pharma Initiates Phase III Clinical Trial for Delgocitinib in China
Denmark-based LEO Pharma A/S has announced the commencement of a China Phase III clinical study...
Coherus Biosciences Awaits FDA Decision on Toripalimab with Year-End Approval Forecast
Coherus Biosciences Inc., (NASDAQ: CHRS), a US-based biotechnology company, has provided an update on the...
Cutia Therapeutics Files for Market Approval of CU-10201 with NMPA for Acne Treatment
Cutia Therapeutics (HKG: 2487), a developer focused on dermatology therapies, has announced the submission of...
United Laboratories Receives FDA Approval for Clinical Study of UBT251 for Obesity Treatment
United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced that...
BioTroy Therapeutics Receives US FDA IND Approval for Anti-Tumor Drug BT02
BioTroy Therapeutics, a Shanghai-based developer of cancer immunotherapies, has announced the receipt of Investigational New...
Sichuan Kelun-Biotech’s KL-A167 and SKB264 Gain Tacit Clinical Trial Approval in China
The Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...
EC Approves AbbVie’s Tepkinly for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its bispecific...
Sanofi’s Altuviiio Receives Marketing Approval from Japan’s MHLW for Hemophilia A Treatment
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...
Japan’s MHLW Approves Eisai and BioArctic’s Leqembi for Alzheimer’s Treatment
The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted approval to Eisai...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Two Cancer Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...